[HTML][HTML] Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections
C Feldman, R Anderson - F1000Research, 2020 - ncbi.nlm.nih.gov
The introduction of pneumococcal conjugate vaccines (PCVs) 7 and 13 into national
childhood immunization programs in the US in 2000 and 2010, respectively, proved to be …
childhood immunization programs in the US in 2000 and 2010, respectively, proved to be …
Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available …
MS Niederman, T Folaranmi, UK Buchwald… - Expert Review of …, 2021 - Taylor & Francis
Introduction: Routine pneumococcal vaccination for adults aged≥ 60 or≥ 65 years and
those with underlying at-risk and high-risk conditions is recommended in many countries …
those with underlying at-risk and high-risk conditions is recommended in many countries …
[HTML][HTML] The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017
S Wijayasri, K Hillier, GH Lim, TM Harris, SE Wilson… - PLoS …, 2019 - journals.plos.org
Background Ontario, Canada introduced a publicly-funded 13-valent pneumococcal
conjugate vaccine (PCV13) for infants in 2010, replacing the 10-valent (PCV10, 2009–2010) …
conjugate vaccine (PCV13) for infants in 2010, replacing the 10-valent (PCV10, 2009–2010) …
[HTML][HTML] Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low-and middle-income countries
By 2050, the number of adults over 65 years of age will be double the under-5 population,
and heavily concentrated in low-and middle-income countries. Population growth and …
and heavily concentrated in low-and middle-income countries. Population growth and …
[HTML][HTML] Age-dependent serotype-associated case-fatality rate in invasive pneumococcal disease in the autonomous community of madrid between 2007 and 2020
S De Miguel, P Latasa, J Yuste, L García, M Ordobás… - Microorganisms, 2021 - mdpi.com
The aim of this study was to investigate the serotype-associated fatality rate in cases of
invasive pneumococcal disease (IPD) in the Spanish region of Madrid between 2007 and …
invasive pneumococcal disease (IPD) in the Spanish region of Madrid between 2007 and …
Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes
KM Nolan, ME Bonhomme, CJ Schier, T Green… - Bioanalysis, 2020 - Future Science
Background: To streamline and improve throughput, the agar-based multiplexed
opsonophagocytic killing assay (MOPA) was optimized and validated on a microcolony …
opsonophagocytic killing assay (MOPA) was optimized and validated on a microcolony …
[HTML][HTML] Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada
M Wilson, M Wasserman, T Jadavi, M Postma… - Infectious diseases and …, 2018 - Springer
Abstract Introduction Pneumococcal conjugate vaccines (PCVs) have been available in
Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization …
Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization …
[HTML][HTML] Increasing pneumococcal vaccine uptake in older adults: a scoping review of interventions in high-income countries
Background There is low uptake of the pneumococcal vaccination in eligible older adults,
even in high-income countries that offer routine and universal vaccination programs …
even in high-income countries that offer routine and universal vaccination programs …
Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions …
SS Ahmed, T Pondo, W Xing, L McGee… - Clinical Infectious …, 2020 - academic.oup.com
Background The 13-valent pneumococcal vaccine (PCV13) was introduced for US children
in 2010 and for immunocompromised adults≥ 19 years old in series with the 23-valent …
in 2010 and for immunocompromised adults≥ 19 years old in series with the 23-valent …
Impact of pneumococcal vaccination on pneumonia hospitalizations and related costs in Ontario: a population-based ecological study
Abstract Background In Ontario, Canada, pneumococcal conjugate vaccine (PCV) was
approved for infants in 2001 and became part of the publicly funded routine immunization …
approved for infants in 2001 and became part of the publicly funded routine immunization …
